Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with Inhibitors

Next Previous
Trial Profile

A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with Inhibitors

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Concizumab (Primary) ; Eptacog alfa (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Proof of concept; Therapeutic Use
  • Acronyms explorer™4
  • Sponsors Novo Nordisk

Most Recent Events

  • 14 Dec 2021 Results (N=61) from phase 2 trials explorer4 (NCT03196284) and explorer5 (NCT03196297) describing surgeries and diagnostic procedures presented at the 63rd American Society of Hematology Annual Meeting and Exposition
  • 14 Dec 2021 Results of an exploratory pooled analyses (of explorer4 (NCT03196284) and explorer5 (NCT03196297) phase 2 trials) assessing changes in HRQoL after long-term concizumab treatment presented at the 63rd American Society of Hematology Annual Meeting and Exposition
  • 08 Dec 2020 Results from the extension part assessing safety and longer term efficacy presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top